As of June 21, 2025, Redwood Pharma AB (REDW.ST) reports a ROE (Return on Equity) of -104.42%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Redwood Pharma AB's ROE (Return on Equity)
Over recent years, Redwood Pharma AB's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2023-12-31 | -104.42% |
| 2022-12-31 | -85.20% |
| 2021-12-31 | -131.15% |
| 2020-12-31 | -205.23% |
| 2019-12-31 | -129.71% |
This slight downward trend highlights how Redwood Pharma AB manages its efficiency in generating profits from shareholders' equity over time.
Comparing Redwood Pharma AB's ROE (Return on Equity) to Peers
To better understand Redwood Pharma AB's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Redwood Pharma AB (REDW.ST) | -104.42% |
| Orexo AB (ORX.ST) | 160.73% |
| Camurus AB (CAMX.ST) | 13.02% |
| Recipharm AB (publ) (RECI B.ST) | 4.61% |
| Swedencare AB (publ) (SECARE.ST) | 1.23% |
| Karo Pharma AB (KARO.ST) | -0.30% |
Compared to its competitors, Redwood Pharma AB's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.